Steffen Walter, Ph.D
Chief Scientific Officer
Dr Steffen Walter co-founded Immatics US, Inc. and joined it in 2015 as Chief Scientific Officer. In 2005, Dr Walter joined Immatics Biotechnologies GmbH, the parent company of Immatics US, Inc., as Director and Head of Immunology and later VP Immunology after having successfully completed his PhD on human T-cell biology at the University of Tuebingen (Germany).
At Immatics Biotechnologies GmbH his focus was to enable decision-making in clinical development by gathering the most relevant immunological biomarkers in about 10 phase I-III clinical trials within a GCP environment. This included the completion of one of the largest laboratory networks worldwide to collect standardized PBMC samples from multi-centric clinical trials in Europe, USA and Asia (72 labs) as well as the development of multiple cellular biomarkers to comprehensively define the immune status of a patient as a potential stratification strategy for personalized immunotherapy. Finally, his team of >20 FTEs pre-clinically validated the immunogenicity of novel antigens and discovered novel T-cell receptors.
Following creation of a business plan for development of innovative adoptive cell therapies based on novel targets discovered by Immatics joined with cellular technologies developed by leading scientists at the MD Anderson Cancer Center, Steffen Walter co-founded Immatics US, Inc. in 2015 and contributed to raising over $60m of funding including a $20m CPRIT grant by the State of Texas.
Steffen Walter is inventor on numerous patents and patent applications and has co-authored more than 30 publications in peer-reviewed journals including Nature Medicine, Cell Reports, Brain and Blood.